THE secretory leukocyte protease inhibitor (SLPI) is a low-molecular-weight inhibitor of proteases, such as elastase and cathepsin G which are released from leukocytes during phagocytosis. The purpose of this study was to determine whether or not SLPI is able to inhibit IgE-mediated histamine release. Nasal mucosa from 11 test subjects without atopic disposition was used for this *in vitro* study. We found that SLPI inhibited histamine release in a dose-dependent way but was without influence on the spontaneous release.

Key words: SLPI, IgE, chymase, histamine, nasal mucosa

IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release

U. Westin,¹ E. Lundberg² and K. Ohlsson^{2,CA}

¹Department of Otolaryngology and Head and Neck Surgery, and ²Department of Surgical Pathophysiology, University Hospital of Malmö, University of Lund, SE-205 02 Malmö, Sweden

^{CA}Corresponding Author
Fax: (+46) 40 336240

Introduction

Secretory leukocyte protease inhibitor (SLPI) is a non-glycosylated, acid-stable, neutral serine antiprotease first described by Haendle *et al.* in 1965.¹ Isolation of native inhibitor (SLPI) from parotid juice allowed the determination of its amino acid sequence.² SLPI is an important regulator of proteases such as granulocyte elastase and cathepsin G. It prevents these enzymes from inhibiting the mucociliary activity in the airways during purulent infection.^{3–7} It is found in great amounts in nasal secretion and is thought to be the major inhibitor of granulocyte elastase in these secretions, while α 1-PI plays a minor role.^{8,9}

Mast cells initiate hypersensitive reactions by binding IgE to high-affinity receptors within the cell membrane in response to allergen challenge. This response causes a rapid release of several mediators, such as histamine and proteases.^{10,11} SLPI has been found to inhibit one of these enzymes, namely chymase.^{12,13} It has been found to be the fastest reacting chymase inhibitor compared with plasma inhibitors such as α 1-PI and α 1-antichymotrypsin.¹⁴ Chymase is thought to play an important role in IgE-mediated histamine release by causing mast cell degranulation.^{15–17} Inhibitors of chymase have been shown to inhibit IgE-mediated histamine release from isolated mast cells, probably after incorporation into mast cell granules. This implies that chymase may play a role in the stimulation of the IgE-mediated activation/secretion response.^{18,19} It has also been demon-

strated that SLPI increases in nasal secretion when patients with atopic disposition are exposed to allergen and histamine.²⁰ Neutral serine proteases such as granulocyte elastase, cathepsin G and mast cell chymase are potent secretagogues for airway gland serous cells. Histamine also degranulates serous cells, but is not such a potent secretagogue as these proteases.^{21–23}

The purpose of this study is to report the effect of SLPI on IgE-mediated histamine release from nasal mucosa *in vitro*. Another objective was to examine whether IgE-stimulation of nasal mucosa caused an increase in SLPI secretion.

Materials and Methods

Nasal mucosa was obtained from 11 patients undergoing conchotomies of the inferior turbinate due to nasal congestion. They were otherwise healthy patients with no known atopic predisposition. After surgery the mucosa was immediately transported to the laboratory in a sterile test tube. The mucosa from each patient was then separated from the osseous part and divided into five equally sized pieces with a scalpel. Each piece was weighed and put into a sterile test tube containing Earle's M-199 salt, (GIBCO BRL, Life Technology, Täby, Sweden). To stimulate antigen cross-linking of membrane bound IgE and histamine release we used anti-IgE (DAKO, Glostrup, Denmark).¹⁰ RhSLPI was obtained from Synergen Inc, Boulder, CO, USA.

Assay of inhibition of histamine release

The tissue samples from each patients were pre-incubated in 2 ml of the medium for 15 min at 37°C. After preincubation a final concentration of 0, 7.5, 150 μ M rhSLPI were added to three different test tubes and incubated for 15 min at 37°C. Then 15 μ l anti-IgE, 15 g/l, were added to these three test tubes. Inhibition of spontaneous histamine release was measured by incubating one tissue sample with the final concentration of 150 μ M rhSLPI without any anti-IgE-stimulation. One test tube tissue was incubated with medium only. Incubation continued at 37°C. Samples of 200 μ l were taken from each of the five test tube supernatants before (0 min), 15 min after adding rhSLPI and then the following 30, 45, 75 and 135 min.

Histamine release was measured with a commercial radioimmunoassay (RIA)-kit (Immunotech, KEMILA, Sollentuna, Sweden). The RIA-kit was able to detect non-methylated histamine. Briefly, the RIA was performed as follows: step 1, acetylation of standard solution or sample; step 2, 50 μ l acetylated standard or sample and 500 μ l tracer was added into antibody coated tubes and were then incubated for 18 h at 2–6°C; step 3, the coated tubes were aspirated and the total counts per minutes and bound counts per minutes were registered. Histamine release was expressed as the percentage increase or decrease relative to the sample taken before anti-IgE-stimulation and after incubation with rhSLPI.

Assay of SLPI

Tissue samples from six subjects were treated as previously described. They were preincubated in 2 ml Earle's M-199 salt, for 15 min at 37°C. A medium sample of 200 μ l was removed from each test tube. One tissue sample was incubated in medium only while the other was stimulated with anti-IgE. Then 200 μ l medium were collected from each test tube at 30, 45, 75 and 135 min after anti-IgE stimulation. SLPI was measured with non-competitive ELISA, as described earlier by Bergenfeldt and Ohlsson.²⁴ Monoclonal mouse-antibodies against SLPI (produced at our laboratory) were made to adhere to wells of microtitre plates.

Diluted samples and standard were then added. An anti-SLPI sheep IgG-antiserum (produced at our laboratory) was then added. Finally, a rabbit anti-sheep IgG antibody, conjugated with alkaline phosphatase (Dakopatt AS, Copenhagen, Denmark), was added.

Alkaline phosphatase cleaved the substrate (4-para-nitro-phenyl-phosphate). The substrate was quantified at 405 nm in an automatic Titertec multiscan photometer. To verify the effect of anti-IgE we measured the histamine release as described above. SLPI was expressed as the percentage increase compared with the sample taken before stimulation with anti-IgE.

Statistics

Regression coefficients were calculated for each histamine release curve from each one of the experiments. The hypothesis, i.e. the differences in regression coefficient were tested with a non-parametric Wilcoxon's paired rank sum test.²⁵

The Man-Whitney *U*-test was calculated on the results at 30, 45, 75 and 135 min in order to see if there was a significant increase in SLPI due to IgE-stimulation.

Results

When nasal mucosa from 11 subjects were pre-incubated with SLPI, IgE-mediated histamine release was inhibited in a dose-dependent manner. There was significant inhibition ($P = 0.028$ and $P = 0.015$) of histamine release at SLPI concentrations of 7.5 μ M and 150 μ M. Inhibition was observed after 30 min incubation (Fig. 1). RhSLPI inhibited IgE-mediated histamine release to the level of spontaneous histamine release (Fig. 2), but did not affect histamine release in the absence of IgE stimulation (Fig. 3).

Pronounced IgE-mediated histamine release was observed in the absence of added rhSLPI ($P = 0.0093$) compared with spontaneous histamine release (Fig. 4).

The effect of IgE on nasal mucosal secretion of SLPI was also studied (six subjects). No significant increase in SLPI was observed when nasal mucosa was subjected to IgE stimulation *in vitro*.

FIG. 1. IgE-mediated histamine release in nasal mucosa at various concentrations, 0 μ M ($\circ$), 7.5 μ M ($\bullet$), 150 μ M ($\blacktriangle$) SLPI. There was a significant inhibition ($P = 0.028$ and $P = 0.015$) of histamine release at 7.5 μ M and 150 μ M. Statistics are calculated on the regression coefficient from the results of the 11 subjects. This figure shows results from a representative experiment.

FIG. 2. IgE-mediated histamine release in nasal mucosa at various concentration, 7.5 μ M (●) and 150 μ M, (▲) of SLPI compared with spontaneously released histamine (□). SLPI had no influence on spontaneous histamine release.

FIG. 4. Anti-IgE induced histamine release in nasal mucosa (○) compared with spontaneous release (■). This figure demonstrates the effect of IgE on histamine release in nasal mucosa.

FIG. 3. Spontaneously released histamine in nasal mucosa incubated with SLPI, 150 μ M, (□) compared with spontaneously released histamine in the absence of SLPI (■). No significant inhibition of histamine release was seen in the absence of IgE-stimulation.

Discussion

Recent studies indicate that SLPI probably plays a role as a regulator in IgE-mediated reactions, perhaps by inhibiting chymase activity.^{12,13} Chymase is a serine protease which resides in mast cell granules.^{16,26,27} Mast cell degranulation is most likely caused by chymase, thus inducing histamine release.^{15,17-19} We have shown that SLPI inhibits IgE-mediated histamine release in a dose-dependent manner in explanted human nasal mucosa (Fig. 1). SLPI inhibits histamine release to the level of spontaneous release (Fig. 2). These results support the suggestion that SLPI may be an important participant in allergic reactions. The

findings of Dietze *et al.*¹² suggest that preincubating tonsillar mast cells with r-MPI (SLPI) for 30 min had no effect, while incubation for 120 min restricted histamine release to the level of spontaneous release. Their study indicated that the inhibitor may not have an impact on immediate hypersensitive reactions, but is of greater importance to prolonged allergen exposure. By incubating human nasal mucosa with SLPI, we found pronounced inhibition of histamine release after 30 min, supporting the importance of SLPI as a regulator in immediate hypersensitive reactions. Whether or not SLPI forms complexes with chymase intra- or extracellularly is not known. Antibodies of chymase are incorporated into mast cell granules and inhibit histamine release, as shown by Kido *et al.*¹⁸ However, mast cells granules contain SLPI,²⁸ which may indicate that the inhibitor is able to penetrate the cell membrane and act as a regulator inside the cell. It has been shown that SLPI increases in nasal secretion in allergic subjects when they are exposed to allergens.²⁰ Serine proteases such as elastase, cathepsin G and chymase are potent secretagogues for airway gland serous cells.²¹⁻²⁴ We proposed that chymase may also stimulate the secretion of SLPI. By incubating nasal mucosa with anti-IgE, mast cell chymase is activated and may be able to stimulate the serous cells of nasal mucosa. No significant increase in SLPI secretion could be seen, which may suggest that a nervous component is required to increase secretion in response to this kind of stimulation. In conclusion, our results obtained from experiments with intact human nasal mucosa, support the theories that SLPI plays a role in type 1 reactions by inhibiting histamine release, and that IgE does not affect SLPI secretion in nasal mucosa *ex vivo*.

References

1. Hændle H, Fritz H, Trautschold I, Werle E. Über einen hormonhängigen Inhibitor für proteolytische Enzyme in menschlichen accessorischen Geschlechtsrüsen und im Sperma. *Hoppe-Seyler's Physiol Chem* 1965; **434**: 185–188.
2. Thomson RC, Ohlsson K. Isolation properties and complete amino acid sequence of human secretory protease inhibitor, a potent inhibitor of leucocyte elastase. *Proc Natl Acad Sci USA* 1986; **83**: 6692–6696.
3. Hochstrasser K, Reichert R, Schwartz S, Werle E. Isolierung und Charakterisierung eines Proteasen Inhibitors aus menschlichen bronkial Sekret. *Hoppe-Seyler's Z Physiol Chem* 1972; **353**: 221.
4. Ohlsson K, Tegner H. Granulocyte collagenase, elastase and plasma protease inhibitor in purulent sputum. *Eur Clin Invest* 1975; **5**: 221–227.
5. Ohlsson K, Tegner H. Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor. *Scand J Clin Lab Invest* 1976; **36**: 437–445.
6. Tegner H, Ohlsson K, Toremalm NG, Mecklenburg CV. Effects of human leukocyte enzymes on tracheal mucosa and its mucociliary activity. *Rhinology* 1979; **17**: 199–206.
7. Seemüller U, Arnold M, Fritz H, et al. The acidstable proteinase inhibitor of human mucous secretions (HUSI, antileucoprotease). *FEBS Lett* 1986; **199**: 43–48.
8. Fryksmark U, Jannert M, Ohlsson K, Whil J-Å, Tegner H. Secretory leukocyte protease inhibitor in normal, allergic and virus induced nasal secretions. *Rhinology* 1989; **27**: 97–103.
9. Westin U, Fryksmark U, Polling Å, Ohlsson K. Localisation of secretory leukocyte proteinase inhibitor mRNA in nasal mucosa. *Acta Otolaryngol* 1994; **114**: 199–202.
10. Igarashi Y, Kurosawa O, Ishikawa Y, Miyachi H, et al. Characteristics of histamine release from cultured human mast cells. *Clin Exp Allergy* 1996; **26**: 597–602.
11. Wasserman SI. Mediators of immediate hypersensitivity. *J Allergy Clin* 1983; **72**: 101–113.
12. Dietze SC, Sommerhoff CP, Fritz H. Inhibition of histamine release from human mast cells ex vivo by natural and synthetic chymase inhibitors. *Biol Chem Hoppe-Seyler* 1990; **371**: 75–79.
13. Fink E, Nettelbeck R, Fritz H. Inhibition of mast cell chymase by eglin c and antileucoprotease (HUSI). *Biol Chem Hoppe-Seyler* 1990; **371**: 75–79.
14. Walter M, Plotnik M, Schechter NM. Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin. *Arch Biochem Biophys* 1996; **327**: 81–88.
15. Schick B, Austen KE, Schwartz LB. Activation of rat serosal mast cells by chymase, an endogenous secretory granule protease. *J Immunol* 1984; **135**: 2571–2577.
16. Okuno-Kaneda S, Saito T, Kawasaki Y, Ischikawa A, Tomita K. Properties of proteases in mast cell granules. *Biochem Pharmacol* 1980; **29**: 1715–1722.
17. Hultsch T, Ennis M, Heidtmann HH. The role of chymase in ionophore-induced histamine release from human pulmonary mast cells. *Advances in experimental medicine and biology. Plenum Press* 1988; **240**: 133–136.
18. Kido H, Fukusen N, Katuma N. Antibodies and inhibitors of chymase are incorporated into mast cell granules and inhibit histamine release. *Biol Chem Hoppe-Seyler* 1988; **369**: 95–100.
19. Kido H, Fukusen N, Katuma N. Antibody and inhibitor of chymase inhibit histamine release in immunoglobulin E-activated mast cells. *Biochem Int* 1985; **10**: 863–871.
20. Hee Lee Ch, Igarashi Y, Hohman RJ, Kaulbach H, White MV, Kaliner MA. Distribution of secretory leukoprotease inhibitor in human nasal airway. *Am Rev Respir Dis* 1993; **147**: 710–716.
21. Sommerhoff CP, Caughey GH, Finkbeiner WE, Lazarus SC, Basbaum CB, Nadel JA. Mast cell chymase a potent secretagogue for airway gland serous cells. *J Immunol* 1989; **142**: 2450–2456.
22. Sommerhoff CP, Fang KC, Nadel JA, Caughey H. Classical second messenger are not involved in proteinase-induced degranulation of airway gland cells. *Am J Physiol* 1996; **271**: 796–803.
23. Sommerhoff CP, Nadel JP, Basbaum CB, Caughey H. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. *J Clin Invest* 1990; **85**: 682–689.
24. Bergenfeldt M, Ohlsson K. Protease-antiprotease levels and whole-blood chemiluminescence in acute peritonitis. *Gastroent Japon* 1993; **28**: 687–698.
25. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. *Br Med J* 1990; **300**: 230–235.
26. Irani A-MA, Schwartz LB. Human mast cell heterogeneity. *Allergy Proc* 1994; **15**: 303–308.
27. Irani A-MA, Bradford TR, Kepley ChL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-trypsin and anti-chymase antibodies. *J Histochem Cytochem* 1989; **37**: 1509–1515.
28. Westin U, Polling Å, Ohlsson K. Human mast cells contain SLPI (secretory leukocyte proteinase inhibitor): demonstrated by immunohistochemistry and in situ hybridisation. Submitted.

ACKNOWLEDGEMENTS. This study was supported by grants from: The Swedish Medical Research Council (3910), the Foundations of Alfred Österlund and Johan and Greta Koch, the Medical Research Foundations of the University Hospital Malmö and the Medical Faculty, Lund University. Statistical guidance by medical statistician Jan-Åke Nilsson, University Hospital Malmö.

**Received 19 January 1998;
accepted in revised form 16 March 1998**